Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.
Ma, Bo
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. [electronic resource] - Acta pharmacologica Sinica Apr 2012 - 479-89 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1745-7254
10.1038/aps.2011.177 doi
Animals
Bone Density--drug effects
Bone and Bones--drug effects
Female
Fructosediphosphates--pharmacology
Humans
Immunologic Factors--pharmacology
Insulin-Like Growth Factor I--analysis
Osteoporosis, Postmenopausal--blood
Osteoprotegerin--blood
Oxidative Stress--drug effects
RANK Ligand--blood
Rats
Rats, Sprague-Dawley
Receptor Activator of Nuclear Factor-kappa B--blood
Signal Transduction
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. [electronic resource] - Acta pharmacologica Sinica Apr 2012 - 479-89 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1745-7254
10.1038/aps.2011.177 doi
Animals
Bone Density--drug effects
Bone and Bones--drug effects
Female
Fructosediphosphates--pharmacology
Humans
Immunologic Factors--pharmacology
Insulin-Like Growth Factor I--analysis
Osteoporosis, Postmenopausal--blood
Osteoprotegerin--blood
Oxidative Stress--drug effects
RANK Ligand--blood
Rats
Rats, Sprague-Dawley
Receptor Activator of Nuclear Factor-kappa B--blood
Signal Transduction